DRI HEALTHCARE TRUST |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.36 CAD | -1.09% |
|
-2.85% | +31.09% |
Presentation Operator MessageOperator (Operator)Good morning, everyone. Welcome to DRI Healthc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
DRI Healthcare Trust is a Canada-based company, which is engaged in providing financing to advance innovation in the life sciences industry. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It is acquiring approximately 70 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. The Companyâs portfolio includes Empaveli, Eylea, Natpara, Omidria, Rydapt, Simponi, Syfovre, Vonjo, Zejula and Zytiga. Its therapeutic areas include influenza, endocrinology, ophthalmology, dermatology, oncology, neurology, autoimmune diseases, heme-onc, lysosomal storage disorder, respiratory diseases, oncology and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis, Johnson & Johnson, and others.
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.95
USD
Average target price
15.3
USD
Spread / Average Target
+28.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.09% | 674M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DHT.U Stock
- News DRI Healthcare Trust
- Transcript : DRI Healthcare Trust, Q3 2023 Earnings Call, Nov 14, 2023
